Steven Cohen’s Insys Therapeutics, Inc. INSY Stock Holding History

Steven Cohen’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-435,000	Closed	-$4.57M	–	1088
2017 Q1	$4.57M	Buy	435,000 +86,373	+25%	+$920K	0.03%	545
2016 Q4	$3.21M	Sell	348,627 -18,516	-5%	-$209K	0.02%	506
2016 Q3	$4.33M	Buy	+367,143	New	+$5.58M	0.03%	444
2015 Q2	–	Sell	-65,200	Closed	-$1.9M	–	922
2015 Q1	$1.9M	Sell	65,200 -1,142,300	-95%	-$30.2M	0.01%	561
2014 Q4	$25.5M	Sell	1,207,500 -144,030	-11%	-$2.85M	0.18%	179
2014 Q3	$26.2M	Buy	1,351,530 +1,014,130	+301%	+$15.9M	0.2%	143
2014 Q2	$5.27M	Buy	+337,400	New	+$5.45M	0.03%	446

Other funds holding INSY

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Steven Cohen's INSY Position: Q2 2017 in Review

Steven Cohen sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 435,000 shares — an estimated $4.57M sold.

Steven Cohen first reported a position in INSY in Q2 2014 and held it in 7 quarters. The position peaked at $26.2M in Q3 2014. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

Steven Cohen reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Steven Cohen sold 435,000 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $4.57M.
Steven Cohen first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 7 quarters.
Steven Cohen's Insys Therapeutics, Inc. position peaked at $26.2M in Q3 2014.
118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on Point72 Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.